PRMT5 and pancreatic neoplasm: One study evaluated the selective MAT2A inhibitor IDE397 in combination with MTA‐cooperative PRMT5 inhibitors in MTAP‐deleted lung adenocarcinoma and pancreas cancer models H838 and BXPC3.21, 30